

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫藥集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 00874)

**ANNOUNCEMENT ON THE PROGRESS OF CONNECTED TRANSACTION
PARTICIPATION IN THE ESTABLISHMENT OF
GP GUANGKAI FUND AND GP LIWAN FUND**

Reference is made to the announcement of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 22 December 2025 (the “**Announcement**”) in relation to the connected transactions involving the participation of GP Fund II, a subsidiary of the Company, in the establishment of GP Guangkai Fund and GP Liwan Fund. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that on 31 December 2025, GP Fund II entered into Partnership Agreement II with GP Capital, Angel Master Fund and Liwan Industrial Investment Fund in respect of the establishment of GP Liwan Fund. Partnership Agreement II formally took effect on the same date, and the principal terms of Partnership Agreement II remain unchanged. The principal terms of Partnership Agreement II and details of this investment are set out in the Announcement.

**The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 31 December 2025

As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Mr. Chen Jiehui, Ms. Cheng Ning, Mr. Cheng Hongjin, Mr. Tang Heping and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.